2-Prop-1-en-2-yl-2,3-dihydropyrano[2,3-g][1,4]benzodioxin-7-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 2-Prop-1-en-2-yl-2,3-dihydropyrano[2,3-g][1,4]benzodioxin-7-one
• 化学式: C₁₄H₁₂O₄
• 分子量: 244.24
• InChiKey: DUECABXXAMFFBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Use of extracts and constituents of leontopodium as enhancers of cholinergic function
  申请人：Leopold-Franzens-Universität Innsbruck

  公开号：EP1792623A1

  公开（公告）日：2007-06-06

  The present invention relates to the use of a plant extract from at least one Leontopodium species for the preparation of a medicament for the treatment of diseases which can be modulated by the selective inhibition of the enzyme acetylcholinesterase and/or increase of acetylcholine concentration at the cholinergic synapse.

  本发明涉及使用至少一种Leontopodium物种的植物提取物制备药物，用于治疗可通过选择性抑制乙酰胆碱酯酶和/或增加胆碱能突触处的乙酰胆碱浓度来调节的疾病。
• NOVEL AGENTS FOR PREVENTING AND TREATING DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION
  申请人：DSM IP Assets B.V.

  公开号：EP1802298A2

  公开（公告）日：2007-07-04
• Novel Agents for Preventing and Treating Disorders Connected to Impaired Neurotransmission
  申请人：De Saizieu Antoine

  公开号：US20070293563A1

  公开（公告）日：2007-12-20

  The present invention refers to coumarin ethers of the formula (I), wherein R 1 is H, OH or (E)-3-methyl-but-2-enyl, R 2 is selected from the group consisting of methyl, 3-(4,5-dihydro-5,5-dimethyl-4-furanon-2-yl)-2-(E/Z)-butenyl, (E/Z)-3,7-dimethylocta-2,6-dienyl, 7-hydroxy-3,7-dimethyl-2-octen-6-on-yl and (E/Z, E/Z)-1-acetyl-oxy-3,7,11,11-tetramethyl-undeca-2,7-dien-10-on-yl, R 3 is H, R 1 and R 2 O together for the group —O—C(C(═CH 2 )CH 3 )H—CH 2 —O— or the group —C(H)═C(H)—C(CH 3 ) 2 —O— or R 2 O and R 3 together form the group —O—C(H)(C(CH 3 ) 2 (H)—O—C(O)CH 3 )—CH 2 —, preferably to obliquin, for use as medicaments, especially for the treatment and/or prevention of disorders connected to impaired neurotransmission, as well as to dietary and pharmaceutical compositions and plant extracts containing such coumarin ethers and their uses.
• Methods and compositions for treating metabolic disorders
  申请人：Mootha Vamsi Krishna

  公开号：US20090143279A1

  公开（公告）日：2009-06-04

  The present invention provides methods of treating of disorders characterized by defective mitochondrial activity. In particular compounds of the present invention can be used in the treatment metabolic diseases and neurodegenerative diseases. The methods are also useful to increase oxidative phosphorylation or to decrease reactive oxygen species (ROS) production in a subject in need thereof.
• SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST
  申请人：Califano Andrea

  公开号：US20090269772A1

  公开（公告）日：2009-10-29

  Systems, methods, and apparatus for searching for a combination of compounds of therapeutic interest are provided. Cell-based assays are performed, each cell-based assay exposing a different sample of cells to a different compound in a plurality of compounds. From the cell-based assays, a subset of the tested compounds is selected. For each respective compound in the subset, a molecular abundance profile from cells exposed to the respective compound is measured. Targets of transcription factors and post-translational modulators of transcription factor activity are inferred from the molecular abundance profile data using information theoretic measures. This data is used to construct an interaction network. Variances in edges in the interaction network are used to determine the drug activity profile of compounds in the subset of compounds. The drug activity profiles are used to form a filter set of compound combinations from the subset of compounds.